Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | STAT1 | P42224 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627822 | 0.98 | GSK3B (0.75) | GSK3BHDAC1HDAC8ALDH1A1MAPT | |
| SCHEMBL541208 | 0.84 | GSK3B (1.00) | GSK3BHDAC8ALDH1A1MAPTHPGD | |
| SCHEMBL11379783 | 0.84 | HDAC1 (0.57) | GSK3BHDAC1HDAC8ALDH1A1MAPT | |
| SCHEMBL655256 | 0.83 | GSK3B (0.69) | GSK3BHDAC8ALDH1A1MAPTNPC1 | |
| SCHEMBL14123719 | 0.83 | GSK3B (0.69) | GSK3BALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL2201934 | 0.82 | HTT (0.64) | GSK3BHDAC1HDAC8ALDH1A1MAPT | |
| SCHEMBL10418628 | 0.82 | ALDH1A1 (0.59) | GSK3BHDAC1HDAC8ALDH1A1MAPT | |
| SCHEMBL12719169 | 0.81 | MAPT (0.58) | GSK3BHDAC1HDAC8ALDH1A1MAPT | |
| Bromide SCHEMBL14054623 | 0.81 | GSK3B (0.67) | GSK3BALDH1A1TSHRLMNAHSD17B10 | |
| Bromide SCHEMBL8084816 | 0.81 | GSK3B (0.67) | GSK3BALDH1A1TSHRLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136617-A1 | SMALL MOLECULES CXCR4 AGONISTS, METHOD OF SYNTHESIS, AND METHOD OF USE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-05-01 | — | — | US | disclosed |
| WO-2023150377-A1 | SMALL MOLECULE CXCR4 AGONISTS, METHOD OF SYNTHESIS, AND METHOD OF USE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-08-10 | — | — | WO | disclosed |
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190048002-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190048003-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-10138234-B2 | 2-phenyl or 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-11-27 | — | — | US | disclosed |
| EP-2991983-B1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-A]PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-20160244441-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-7772260-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| EP-1467981-A1 | 4(HETERO-) ARYL SUBSTITUTED (THIA-/OXA-/PYRA) ZOLES FOR INHIBITION OF TIE-2 | Kylix Pharmaceuticals B.V. (NL) | 2004-10-20 | — | — | EP | disclosed |
| EP-1463735-A1 | IMIDAZO[2,1-B]-1,3,4-THIADIAZOLE SULFONAMIDES | Aegera Therapeutics Inc. (CA) | 2004-10-06 | — | — | EP | disclosed |
| US-6756374-B2 | CYCLIN-DEPENDENT KINASE INHIBITORS SUCH AS (4-AMINO-2-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-5-THIAZOLYL) (2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)METHANONE FOR TREATMENT OF BREAST, LUNG, COLON, AND PROSTATE CANCER/TUMORS | HOFFMANN-LA ROCHE INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | DING QINGJIE (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | DING QINGJIE (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003062215-A1 | 4(HETERO-) ARYL SUBSTITUTED (THIA-/OXA-/PYRA) ZOLES FOR INHIBITION OF TIE-2 | KYLIX PHARMACEUTICALS B.V. (NL) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003051890-A1 | IMIDAZO [2,1-B]-1,3,4-THIADIAZOLE SUFLONAMIDES | AEGERA THERAPEUTICS INC. (CA) | 2003-06-26 | — | — | WO | disclosed |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CHEN LI (US) | 2002-10-17 | — | — | US | disclosed |
| US-6329399-B1 | Antifungal amine derivatives and processing for producing the same | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1020426-A1 | AMINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | GSK3B 1797/4885HDAC1 78/4885HDAC8 190/4885 |
| US-20190048003-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTR3D, GDI2, GDI1 | GSK3B 4403/4885HDAC1 2527/4885HDAC8 2837/4885 |
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HTR3D, PTGDR2, PTGIR | GSK3B 4244/4885HDAC1 3539/4885HDAC8 2597/4885 |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | GSK3B 1797/4885HDAC1 78/4885HDAC8 190/4885 |
| US-10138234-B2 | 2-phenyl or 2-hetaryl imidazol[1,2-a]pyridine derivatives | CNKSR1, HCAR3, HCAR1 | GSK3B 4112/4885HDAC1 1549/4885HDAC8 2235/4885 |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | CDK4, CDK2, CDKL4 | GSK3B 994/4885HDAC1 94/4885HDAC8 249/4885 |
| US-20160244441-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTT, HCAR2, HCAR3 | GSK3B 3680/4885HDAC1 2117/4885HDAC8 2935/4885 |
| US-20190048002-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTR3D, GDI2, GDI1 | GSK3B 4403/4885HDAC1 2527/4885HDAC8 2837/4885 |
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | TBXA2R, HRH2, CYP4F3 | GSK3B 4628/4885HDAC1 2646/4885HDAC8 2883/4885 |
| US-20250136617-A1 | SMALL MOLECULES CXCR4 AGONISTS, METHOD OF SYNTHESIS, AND METHOD OF USE | CXCR4, CXCL12, CXCR1 | GSK3B 889/4885HDAC1 2784/4885HDAC8 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.